Related Experiment Video
Updated: Mar 14, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
The integrated 31-gene expression profile test identifies low-risk patients with cutaneous melanoma who can forego
Timothy Beard1, J Michael Guenther2, Stanley P Leong3
1Summit Medical Group, Bend, OR, USA.
Aims:
Prospectively confirm use of the integrated 31-gene expression profile test (i31-SLNB) in patients with cutaneous melanoma to predict sentinel lymph node biopsy (SLNB) positivity and assess recurrence rates in those considered low risk by i31-SLNB who did not have an SLNB.
Methods:
Patients with T1-T4 tumors being considered for SLNB who received 31-gene expression profile (31-GEP) testing in the multi-center, prospective DECIDE study were included (n = 912). Kaplan-Meier analysis was used to estimate recurrence-free survival (RFS).
Results:
Among 430 patients with T1-T4 tumors who had an SLNB, the positivity rate was 2.6% (3/114) in those with <5% i31-SLNB-predicted risk versus 21.4% (28/131) in those with >10% predicted risk. Among those with T1-T2a tumors who had an SLNB (n = 359), the positivity rate was 1.8% (2/111) in those with <5% predicted risk versus 16.7% (12/72) in those with >10% predicted risk. The 3-year RFS rate was 97.8% in patients with i31-SLNB <5% predicted risk.
Conclusions:
In this multi-center prospective study, the i31-SLNB accurately predicted SLN positivity, and patients who avoided SLNB based on i31-SLNB results had high RFS. Thus, the i31-SLNB identifies low-risk patients who may consider foregoing the SLNB procedure.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018